España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

abx advanced biochemical compounds gmbh - psma-1007 (18f) - soluciÓn inyectable - 2.000 mbq/ml inyectable 20 ml - psma-1007 (18f) 2000 mbq - psma-1007 (18f)

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

abx advanced biochemical compounds gmbh - psma-1007 (18f) - soluciÓn inyectable - 1.300 mbq/ml inyectable 20 ml - psma-1007 (18f) 1300 mbq - psma-1007 (18f)

Guatemala - español - Gobierno de Guatemala, Ministerio de Salud Pública y Asistencia Social (Departamento de Regulación y Control de Productos Farmacéuticos y Afines)

spsm pharmaceutical - comprimido recubierto - 30 mg

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

ciclotron peru s.a. - laboratorio - solucion inyectable - por vial ml - - sodium fluoride (18f)

Perú - español - DIGEMID (Dirección General de Medicamentos, Insumos y Drogas)

laboratorios portugal s.r.l. - crema

Unión Europea - español - EMA (European Medicines Agency)

novartis europharm limited  - gozetotide - imágenes de radionúclidos - radiofármacos de diagnóstico - este medicamento es solo para uso diagnóstico. locametz, after radiolabelling with gallium 68, is indicated for the detection of prostate specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high risk pca prior to primary curative therapy,suspected pca recurrence in patients with increasing levels of serum prostate specific antigen (psa) after primary curative therapy,identification of patients with psma positive progressive metastatic castration resistant prostate cancer (mcrpc) for whom psma targeted therapy is indicated (see section 4.

Unión Europea - español - EMA (European Medicines Agency)

novartis europharm limited  - lutetium (177lu) vipivotide tetraxetan - próstata neoplasias, resistente a la castración - radiofármacos terapéuticos - pluvicto in combination with androgen deprivation therapy (adt) with or without androgen receptor (ar) pathway inhibition is indicated for the treatment of adult patients with progressive prostate-specific membrane antigen (psma)-positive metastatic castration-resistant prostate cancer (mcrpc) who have been treated with ar pathway inhibition and taxane based chemotherapy.

Unión Europea - español - EMA (European Medicines Agency)

curium pet france - piflufolastat (18f) - neoplasmas prostáticos - radiofármacos de diagnóstico - este medicamento es solo para uso diagnóstico. pylclari is indicated for the detection of prostate-specific membrane antigen (psma) positive lesions with positron emission tomography (pet) in adults with prostate cancer (pca) in the following clinical settings:primary staging of patients with high-risk pca prior to initial curative therapy,to localize recurrence of pca in patients with a suspected recurrence based on increasing serum prostate-specific antigen (psa) levels after primary treatment with curative intent. pylclari is indicated for use with positron emission tomography (pet).

España - español - AEMPS (Agencia Española de Medicamentos y Productos Sanitarios)

merck sharp & dohme animal health, s.l. - gonadotropina serica equina para uso veterinario - polvo y disolvente para soluciÓn inyectable - excipientes: manitol (e-421), hidrogenofosfato de disodio dihidrato, dihidrogenofosfato de sodio dihidrato, hidrogenofosfato de disodio dihidrato, dihidrogenofosfato de sodio dihidrato, agua para preparaciones inyectables - gonadotropina sérica - cabras, novillas, ovino, vacas

Chile - español - ISPC (Instituto de Salud Pública de Chile)

gedeon richter chile spa - estradiol (como hemihidrato);noretisterona acetato;relugolix - sin formulas